Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta‐analysis. Issue 3 (1st August 2021)
- Record Type:
- Journal Article
- Title:
- Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta‐analysis. Issue 3 (1st August 2021)
- Main Title:
- Effects of pharmacological agents for neurogenic oropharyngeal dysphagia: A systematic review and meta‐analysis
- Authors:
- Cheng, Ivy
Sasegbon, Ayodele
Hamdy, Shaheen - Abstract:
- Abstract: Background: This systematic review and meta‐analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing‐related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74, 1.80], p < 0.001; I 2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non‐significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I 2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09, 2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08, 2.27]; p < 0.001). By contrast, the effects of angiotensin‐converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32, 0.99]; p = 0.43; I 2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03, 0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non‐significant. Within stroke patients, subgroup analysis showed that TRP channel agonistsAbstract: Background: This systematic review and meta‐analysis aimed to evaluate the effects of pharmacological agents for neurogenic oropharyngeal dysphagia based on evidence from randomized controlled trials (RCTs). Methods: Electronic databases were systematically searched between January 1970 and March 2021. Two reviewers independently extracted and synthesized the data. The outcome measure was changed in (any) relevant clinical swallowing‐related characteristics. Key results: Data from 2186 dysphagic patients were collected from 14 RCT studies across a range of pharmacotherapies. The pooled effect size of transient receptor potential (TRP) channel agonists was large compared to placebo interventions (SMD[95%CI] =1.27[0.74, 1.80], p < 0.001; I 2 = 79%). Data were limited for other pharmacological agents and the overall pooled effect size of these agents was non‐significant (SMD [95% CI] =0.25 [−0.24, 0.73]; p = 0.31; I 2 = 85%). When analyzed separately, large effect sizes were observed with Nifedipine (SMD[95%CI] =1.13[0.09, 2.18]; p = 0.03) and Metoclopramide (SMD[95%CI] =1.68[1.08, 2.27]; p < 0.001). By contrast, the effects of angiotensin‐converting enzyme (ACE) inhibitors (SMD[95%CI] = −0.67[−2.32, 0.99]; p = 0.43; I 2 = 61%), Physostigmine (SMD[95%CI] = −0.05[−1.03, 0.93]; p = 0.92) and Glyceryl Trinitrate (GTN) (SMD [95% CI] = −0.01 [−0.11, 0.08]; p = 0.78) were non‐significant. Within stroke patients, subgroup analysis showed that TRP channel agonists had a moderate pooled effect size (SMD[95%CI] =0.74[0.10, 1.39]; p = 0.02; I 2 = 82%) whereas the effects of other agents were non‐significant (SMD[95%CI] =0.40[−0.04, 0.84]; p = 0.07; I 2 = 87%). Conclusions & Inferences: Our results showed that TRP channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing. Abstract : Our systematic review and meta‐analysis found that transient receptor potential (TRP) channel agonists, Nifedipine and Metoclopromide may be beneficial for neurogenic dysphagic patients. Large scale, multicenter clinical trials are warranted to fully explore their therapeutic effects on swallowing. … (more)
- Is Part Of:
- Neurogastroenterology & motility. Volume 34:Issue 3(2022)
- Journal:
- Neurogastroenterology & motility
- Issue:
- Volume 34:Issue 3(2022)
- Issue Display:
- Volume 34, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 34
- Issue:
- 3
- Issue Sort Value:
- 2022-0034-0003-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-08-01
- Subjects:
- drugs -- dysphagia -- meta‐analysis -- pharmacotherapy -- systematic review -- treatment
Gastrointestinal system -- Motility -- Periodicals
Gastrointestinal system -- Innervation -- Periodicals
616.33 - Journal URLs:
- http://www.blackwell-synergy.com/servlet/useragent?func=showIssues&code=nmo ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2982 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/nmo.14220 ↗
- Languages:
- English
- ISSNs:
- 1350-1925
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.371450
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 27151.xml